Patents by Inventor Gary Koppel

Gary Koppel has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Neurotherapeutic composition and method therefor
    Publication number: 20070249523
    Abstract: Neurotherapeutically effective pharmaceutical compositions are described that include carboxypeptidase E inhibitors. One class of carboxypeptidase E inhibitors found to exhibit significant neurotropic activity are ?-lactam compounds, particularly penam and cephem ?-lactam antibiotics and non-antibiotic derivatives thereof.
    Type: Application
    Filed: February 28, 2007
    Publication date: October 25, 2007
    Inventors: Gary Koppel, Michael Chaney
  • ?-lactamyl vasopressin V antagonists
    Patent number: 7268125
    Abstract: Novel 2-(azetidin-2-on-1-yl)alkanedioic acid derivatives and 2-(azetidin-2-on-1-yl)alkoxyalkanoic acid derivatives are described for use in the treatment of disease states responsive to antagonism of the vasopressin V1a receptor
    Type: Grant
    Filed: May 30, 2006
    Date of Patent: September 11, 2007
    Assignee: Azevan Pharmaceuticals, Inc.
    Inventors: Robert F. Bruns, Jr., Christophe D. G. Guillon, Ned D. Heindel, Gary A. Koppel, Marvin J. Miller
  • NEUROTHERAPEUTIC TREATMENT FOR SEXUAL DYSFUNCTION
    Publication number: 20070093466
    Abstract: A method for improving sexual function is described. A mammal suffering from sexual dysfunction or otherwise in need of enhanced sexual function is administered a compound selected from those that are capable of inhibiting the activity of ?-lactams, penicillin-binding protein, carboxypeptidase,. Such compounds, including particularly ?-lactam ring-containing compounds, can be used to formulate pharmaceutical formulations useful for improving sexual function.
    Type: Application
    Filed: November 21, 2006
    Publication date: April 26, 2007
    Inventor: Gary Koppel
  • Therapeutic treatment for sexual dysfunction
    Patent number: 7166626
    Abstract: A method for improving sexual function is described. A mammal suffering from sexual dysfunction or otherwise in need of enhanced sexual function is administered a compound selected from those that are capable of inhibiting the activity of ?-lactams, penicillin-binding protein, carboxypeptidase,. Such compounds, including particularly ?-lactam ring-containing compounds, can be used to formulate pharmaceutical formulations useful for improving sexual function.
    Type: Grant
    Filed: June 18, 2002
    Date of Patent: January 23, 2007
    Assignee: Revaax Pharmaceuticals, LLC
    Inventor: Gary A. Koppel
  • 3-Substituted beta-lactamyl vasopressin v1a antagonists
    Publication number: 20060281728
    Abstract: Novel 2-(azetidin-2-on-1-yl)alkanedioic acids and derivatives thereof are described. Methods for using 2-(azetidin-2-on-1-yl)alkanedioic acids and derivatives thereof in the treatment of disease states responsive to antagonism of the vasopressin V1a receptor are also described.
    Type: Application
    Filed: October 1, 2004
    Publication date: December 14, 2006
    Inventors: Christophe Guillon, Ned Heindel, Gary Koppel, Marvin Miller
  • ?-Lactamyl vasopressin VAntagonists
    Patent number: 7119083
    Abstract: Novel 2-(azetidin-2-on-1-yl)alkanedioic acid derivatives and 2-(azetidin-2-on-1-yl)alkoxyalkanoic acid derivatives are described for use in the treatment of disease states responsive to antagonism of the vasopressin V1a receptor.
    Type: Grant
    Filed: October 11, 2002
    Date of Patent: October 10, 2006
    Assignee: Azevan Pharmaceuticals, Inc.
    Inventors: Robert F. Bruns, Jr., Christophe D. G. Guillon, Ned D. Heindel, Gary A. Koppel, Marvin J. Miller
  • Beta-lactamyl vasopressin V1a antagonists
    Publication number: 20060217364
    Abstract: Novel 2-(azetidin-2-on-1-yl)alkanedioic acid derivatives and 2-(azetidin-2-on-1-yl)alkoxyalkanoic acid derivatives are described for use in the treatment of disease states responsive to antagonism of the vasopressin V1a receptor.
    Type: Application
    Filed: May 30, 2006
    Publication date: September 28, 2006
    Inventors: Robert Bruns, Christophe Guillon, Ned Heindel, Gary Koppel, Marvin Miller
  • Beta-lactamyl vasopressin v1aantagonists
    Publication number: 20040266750
    Abstract: Novel 2-(azetidin-2-on-1-yl)alkanedioic acid derivatives and 2-(azetidin-2-on-1-yl)alkoxyalkanoic acid derivatives are described for use in the treatment of disease states responsive to antagonism of the vasopressin V1a receptor.
    Type: Application
    Filed: June 15, 2004
    Publication date: December 30, 2004
    Inventors: Robert F. Bruns Jr, Christophe D.G. Guillon, Ned E. Heindel, Gary A. Koppel, Marvin J. Miller
  • Neurotherapeutic composition and method
    Publication number: 20040229857
    Abstract: Administration of &bgr;-Lactam compounds, including &bgr;-lactam antibiotics and &bgr;-lactamase inhibitors provides significant neurotropic effects in warm-blooded vertebrates evidenced inter alia by anxiolytic and anti-aggressive behavior modification and enhanced cognition. Therapeutic methods for using such compounds and their pharmaceutical formulations are described.
    Type: Application
    Filed: September 9, 2003
    Publication date: November 18, 2004
    Inventor: Gary A. Koppel
  • Antibiotic composition and method
    Publication number: 20040072815
    Abstract: Novel antibiotic compositions are described. &bgr;-lactam antibiotics are used in combination with a non-&bgr;-lactam inhibitor of NAALADase, the inhibitor in an amount effective to inhibit &bgr;-lactamase activity. The antibiotic compositions can be administered to treat infections caused by &bgr;-lactamase-producing bacterial strains.
    Type: Application
    Filed: August 5, 2003
    Publication date: April 15, 2004
    Inventor: Gary A. Koppel
  • Neurotherapeutic clavulanate composition and method
    Publication number: 20040014739
    Abstract: Administration of clavulanic acid and related compounds at low dosages provides significant neurotropic effects in warm-blooded vertebrates evidenced inter alia by anxiolytic and anti-aggressive behavior and enhanced cognition believed to be mediated by inhibition of neurogenic enzyme activity. Therapeutic methods for using such compounds and their pharmaceutical formulations are described.
    Type: Application
    Filed: July 15, 2003
    Publication date: January 22, 2004
    Inventor: Gary A. Koppel
  • Treatment of behavioral disorders with &bgr;-lactam compounds
    Patent number: 6627625
    Abstract: Administration of &bgr;-lactam compounds including &bgr;-lactam antibiotics and &bgr;-lactamase inhibitors provides significant neurotropic effects in warm-blooded vertebrates evidenced inter alia by anxiolytic and anti-aggressive behavior modification and enhanced cognition. Therapeutic methods for using such compounds and their pharmaceutical formulations are described.
    Type: Grant
    Filed: August 16, 2000
    Date of Patent: September 30, 2003
    Assignee: Revaax Pharmaceuticals, LLC
    Inventor: Gary A. Koppel
  • Neurotherapeutic clavulanate composition and method
    Patent number: 6610681
    Abstract: Administration of clavulanic acid and related compounds at low dosages provides significant neurotropic effects in warm-blooded vertebrates evidenced inter alia by anxiolytic and anti-aggressive behavior and enhanced cognition believed to be mediated by inhibition of neurogenic enzyme activity. Therapeutic methods for using such compounds and their pharmaceutical formulations are described.
    Type: Grant
    Filed: August 16, 2000
    Date of Patent: August 26, 2003
    Assignee: Revaax Pharmaceuticals, LLC
    Inventor: Gary A. Koppel
  • Non-peptidyl vasopressin V1A antagonists
    Patent number: 6610680
    Abstract: This invention provides substituted 2-(azetidinon-1-yl) acetic acid derivatives of Formula II for the antagonism of the vasopressin V1a receptor.
    Type: Grant
    Filed: December 20, 2002
    Date of Patent: August 26, 2003
    Assignee: Eli Lilly and Company
    Inventors: Robert F Bruns, Jr., Robin D G Cooper, Bruce A Dressman, David C Hunden, Stephen W Kaldor, Gary A Koppel, John R Rizzo, Jeffrey J Skelton, Mitchell I Steinberg
  • Neurotherapeutic composition and method therefor
    Publication number: 20030158172
    Abstract: Neurotherapeutically pharmaceutical effective compositions are prepared using carboxypeptidase E inhibitors. One class of carboxypeptidase E inhibitors found to exhibit significant neurotropic activity are &bgr;-lactam compounds, particularly penam and cephem &bgr;-lactam antibiotics and non-antibiotic derivatives thereof.
    Type: Application
    Filed: August 20, 2002
    Publication date: August 21, 2003
    Inventors: Gary A. Koppel, Michael O. Chaney
  • Non-peptidyl vasopressin V1a antagonists
    Patent number: 6521611
    Abstract: This invention provides methods and 2-(azetidin-2-on-1-yl) acetic acid derivatives of Formula I for the antagonism of the vasopressin V1a receptor.
    Type: Grant
    Filed: December 8, 2000
    Date of Patent: February 18, 2003
    Assignee: Eli Lilly and Company
    Inventors: Robert F Bruns, Jr., Robin D G Cooper, Bruce A Dressman, David C Hunden, Stephen W Kaldor, Gary A Koppel, John R Rizzo, Jeffrey J Skelton, Mitchell I Steinberg
  • Neurotherapeutic compositions
    Publication number: 20020183304
    Abstract: Novel neuroprotectant compositions and methods are described. &bgr;-Lactamase inhibitors are used to prevent or reduce loss of neuronal cells and neuronal cell function in patients afflicted with or susceptible to disease states or conditions known to result in or cause neuronal tissue insult.
    Type: Application
    Filed: April 2, 2002
    Publication date: December 5, 2002
    Inventor: Gary A. Koppel
  • Neurotherapeutic use of carboxypeptidase inhibitors
    Patent number: 6489319
    Abstract: Administration of inhibitors of carboxypeptidase E provides significant neurotropic effects in warm-blooded vertebrates evidenced inter alia by anxiolytic and anti-aggressive behavior and enhanced cognition. Certain &bgr;-Lactam antibiotics, most significantly, certain 1-oxa-1-dethia cephems with blood brain barrier transport, exhibit potent therapeutic neurologic activity.
    Type: Grant
    Filed: February 14, 2001
    Date of Patent: December 3, 2002
    Assignee: Revaax Pharmaceuticals, LLC
    Inventors: Gary A. Koppel, Michael O. Chaney
  • Use of &bgr;-lactamase inhibitors as neuroprotectants
    Patent number: 6426342
    Abstract: Novel neuroprotectant methods are described. &bgr;-Lactamase inhibitors are used to prevent or reduce loss of neuronal cells and neuronal cell function in patients afflicted with or susceptible to disease states or conditions known to result in or cause neuronal tissue insult.
    Type: Grant
    Filed: February 13, 2001
    Date of Patent: July 30, 2002
    Assignee: Revaax Pharmaceuticals, LLC
    Inventor: Gary A. Koppel
  • Non-peptidyl vasopressin V1a antagonists
    Publication number: 20020049187
    Abstract: This invention provides methods and 2-(azetidin-2-on-1-yl) acetic acid derivatives of Formula I 1
    Type: Application
    Filed: December 8, 2000
    Publication date: April 25, 2002
    Inventors: Robert F. Bruns, Robin DG Cooper, Bruce A. Dressman, David C. Hunden, Stephen W. Kaldor, Gary A. Koppel, John R. Rizzo, Jeffrey J. Skelton, Mitchell I. Steinberg